Drug intelligence / Profile preview

Humia

Development stage: Phase 3
Lead developer: Huons
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intra-articular Injection

Overview

Humia is an injectable pharmaceutical product developed by Huons Co., Ltd. It is a hyaluronic acid preparation currently undergoing a Phase III clinical trial for the treatment of knee osteoarthritis. Hyaluronic acid is a natural polymer found in synovial fluid, where it acts as a lubricant and shock absorber in joints.

Brand names: HumiaHumia inj.
Other names: sodium hyaluronatehyaluronic acidcross-linked sodium hyaluronate

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on Humia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Humia.

Explore the full profile